The Ensign Group, Inc. reported third-quarter diluted EPS of $1.76, adjusted EPS of $2.03 and revenue of $1.48 billion. It raised 2026 earnings guidance to $7.94 to $8.02 per diluted share from $7.75 to $7.85.
ENSG · Ensign Group, Inc
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
Ensign Group expanded during the nine months ended September 30, 2026 by adding 23 stand-alone and two campus operations, 2,974 beds and 135 senior living units, then entered Florida after adding 18 stand-alone and two campus operations.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q2 FY26 earnings call · Jul 29, 2026TL;DR. Ensign reported record Q2 2026 results with adjusted EPS of $1.92 (+20.8% YoY) and raised its full-year 2026 earnings guidance to $7.75–$7.85 per diluted share and revenue guidance to $5.87–$5.92 billion, driven by occupancy gains, skilled mix expansion, and continued acquisitions.
- + Raised full-year 2026 EPS guidance to $7.75–$7.85 from $7.48–$7.62 and revenue guidance to $5.87–$5.92 billion from $5.81–$5.86 billion.
- − Recently acquired Texas facilities carry higher purchase prices, lower-than-average occupancies, and 'significant clinical and operational hurdles' that will take time to deliver expected returns.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Total rental revenue | $47.7M | FY2026 Q3 | +46.3% |
|
|
|||
| Actual patient days | 3,017,641 | three months ended June 30, 2026 filing | — |
| Actual patient days - Recently Acquired Facility | 447,826 | three months ended June 30, 2026 filing | — |
| Actual patient days - Same Facility | 2,164,347 | three months ended June 30, 2026 filing | — |
| Actual patient days - Transitioning Facility | 405,468 | three months ended June 30, 2026 filing | — |
| Adjusted Earnings Per Share non-GAAP | $1.92 | Three Months Ended June 30, 2026 filing | — |
| Adjusted EBITDA non-GAAP | $181.15M | Three Months Ended June 30, 2026 filing | — |
GAAP → non-GAAP reconciliationEBITDA $162.28M (the result of another reconciliation in this filing)
+$16.17M Stock-based compensation expense
+$2.18M Costs incurred related to system implementations
+$0K Loss (gain) on long-lived assets and business interruption recoveries
+$519K Acquisition related costs
= Adjusted EBITDA $181.15M
|
|||
| Adjusted EBITDAR non-GAAP | $247.56M | Three Months Ended June 30, 2026 filing | — |
GAAP → non-GAAP reconciliationAdjusted EBITDA $181.15M (non-GAAP)
+$66.41M Rent—cost of services
= Adjusted EBITDAR $247.56M
|
|||
| Adjusted EBT non-GAAP | $152.54M | Three Months Ended June 30, 2026 filing | — |
| Adjusted Net Income non-GAAP | $114.31M | Three Months Ended June 30, 2026 filing | — |
| Dollar value of common stock repurchased | $40M | three months ended June 30, 2026 filing | — |
| EBITDA non-GAAP | $162.28M | Three Months Ended June 30, 2026 filing | — |
GAAP → non-GAAP reconciliationGAAP Net income $99.83M
-$96K Less: Net income attributable to noncontrolling interests
-$4.63M Less: Interest income
+$33.84M Add: Provision for income taxes
+$31.41M Add: Depreciation and amortization
+$1.93M Add: Interest expense
= EBITDA $162.28M
|
|||
| FFO non-GAAP | $24.75M | three months ended June 30, 2026 filing | — |
| FFO for Standard Bearer non-GAAP | $24.75M | Three Months Ended June 30, 2026 filing | — |
| Number of campuses at period end | 32 | Three Months Ended June 30, 2026 filing | — |
| Number of facilities at period end | 348 | Three Months Ended June 30, 2026 filing | — |
| Number of facilities at period end - Recently Acquired Facility | 64 | three months ended June 30, 2026 filing | — |
| Number of facilities at period end - Same Facility | 234 | three months ended June 30, 2026 filing | — |
| Number of facilities at period end - Transitioning Facility | 50 | three months ended June 30, 2026 filing | — |
| Occupancy percentage — Operational beds | 82.9% | three months ended June 30, 2026 filing | — |
| Occupancy percentage — Operational beds - Recently Acquired Facility | 76.6% | three months ended June 30, 2026 filing | — |
| Occupancy percentage — Operational beds - Same Facility | 84.1% | three months ended June 30, 2026 filing | — |
| Occupancy percentage — Operational beds - Transitioning Facility | 84.7% | three months ended June 30, 2026 filing | — |
| Other third-party rental income | $3.56M | the three months ended June 30, 2026 filing | +56.5% |
|
|
|||
| Pennant rental income | $4.43M | the three months ended June 30, 2026 filing | +8.5% |
|
|
|||
| Same Facilities occupancy | 84.1% | the three months ended June 30, 2026 filing | — |
| Shares of common stock repurchased | 257K | three months ended June 30, 2026 filing | — |
| Skilled Mix (Days) | 31% | Three Months Ended June 30, 2026 filing | — |
| Skilled Mix (Revenue) | 50% | Three Months Ended June 30, 2026 filing | — |
| Skilled mix by nursing days - Recently Acquired Facility | 26.9% | three months ended June 30, 2026 filing | — |
| Skilled mix by nursing days - Same Facility | 32.2% | three months ended June 30, 2026 filing | — |
| Skilled mix by nursing days - Transitioning Facility | 29.7% | three months ended June 30, 2026 filing | — |
| Skilled mix by nursing revenue - Recently Acquired Facility | 45.1% | three months ended June 30, 2026 filing | — |
| Skilled mix by nursing revenue - Same Facility | 51% | three months ended June 30, 2026 filing | — |
| Total rent expense under the Master Leases | $19.76M | the three months ended June 30, 2026 filing | +16.9% |
|
|
|||
| Total rental income from third-party sources | $7.98M | the three months ended June 30, 2026 filing | +25.6% |
|
|
|||
| Total skilled nursing revenue - Average daily revenue rate | $435.1 | three months ended June 30, 2026 filing | — |
| Transitioning Facilities occupancy | 84.7% | the three months ended June 30, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Care Facilities — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ENSG
this stock
Ensign Group, Inc
|
$10.85B | +6.8% | +18.7% | 27.7 | 2.5% |
|
HCA
HCA Healthcare, Inc.
|
$104.69B | +7.4% | +7.1% | 16.6 | 2.3% |
|
FSNUY
Fresenius SE & Co. KGaA
|
$33.30B | +3.1% | — | — | 0.0% |
|
THC
Tenet Healthcare Corp
|
$22.45B | +41.9% | +0.9% | 8.2 | 2.2% |
|
EHC
Encompass Health Corp
|
$13.53B | +29.9% | +10.5% | 21.5 | 3.7% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Oct 27, 2026
- This year
- 16
The Ensign Group, Inc. reported third-quarter diluted EPS of $1.76, adjusted EPS of $2.03 and revenue of $1.48 billion. It raised 2026 earnings guidance to $7.94 to $8.02 per diluted share from $7.75 to $7.85.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ENSG | +0.5% | +5.7% | +8.8% | +2.5% | +6.8% |
| SPY | -2.3% | -4.8% | -2.9% | -3.1% | +7.4% |
| vs SPY | +2.8% | +10.5% | +11.8% | +5.6% | -0.6% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.